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Abstract: Fibroblast growth factor 21 (FGF21) and adiponectin increase expression of genes 22 
involved in antioxidant pathways, but their roles in mediating oxidative stress and arterial stiffness 23 
with ageing and habitual exercise remain unknown. We explored the role of the FGF21–adiponectin 24 
axis in mediating oxidative stress and arterial stiffness with ageing and habitual exercise. Eighty age- and 25 
sex-matched healthy individuals were assigned to younger sedentary or active (18–36 years 26 
old,n=20 each) and older sedentary or active (45–80 years old,n=20 each) groups. Arterial stiffness 27 
was measured indirectly using pulse wave velocity (PWV). Fasted plasma concentrations of FGF21, 28 
adiponectin and oxidized low-density lipoprotein (oxLDL) were measured. PWV was 0.2-fold 29 
higher and oxLDL concentration was 25.6% higher (both p<0.001) in older than younger adults, 30 
despite no difference in FGF21 concentration (p=0.097) between age groups. PWV (p=0.09) and 31 
oxLDL concentration (p=0.275) did not differ between activity groups but FGF21 concentration was 32 
9% lower in active than sedentary individuals (p=0.011). Adiponectin concentration did not differ 33 
by age (p=0.642) or exercise habits (p=0.821). In conclusion, age, but not habitual exercise, was 34 
associated with higher oxidative stress and arterial stiffness. FGF21 and adiponectin did not differ 35 
between younger and older adults, unlikely mediating oxidative stress and arterial stiffness in 36 
healthy adults.  37 
Keywords:  exercise; ageing; oxLDL; arterial stiffness 38 
 39 
1. Introduction 40 
Arterial stiffness is an independent risk factor for cardiovascular mortality and is involved in 41 
various metabolic diseases [1]. Arterial stiffness, evaluated using arterial tonometry pulse wave 42 
velocity (PWV), increases exponentially with normative ageing even within a healthy population [2]. 43 
The ageing process independently contributes to the development of arterial stiffness, leading to 44 
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functional changes in major arteries [3]. Age-associated arterial stiffness is mainly due to an increase 45 
in oxidative stress [3]. In clinically healthy middle-aged men, a higher circulating concentration of 46 
oxidized low-density lipoprotein  (oxLDL), a marker for oxidative stress, was associated with a 4-47 
fold higher risk of future coronary heart disease [4]. OxLDL concentration was also positively related 48 
to carotid and femoral artery intima-media thickness and plaque occurrence, which promotes arterial 49 
stiffness [4].  50 
While ageing is associated with increased arterial stiffness, exercise training is effective for 51 
ameliorating age-associated arterial stiffness [5]. Compared to their sedentary counterparts, 52 
habitually active individuals have 20–35% lower arterial stiffness [6]. Exercise improves arterial 53 
stiffness mainly through a reduction in oxidative stress. For example, 2–3 sessions (>30 min each 54 
session) of weekly exercise improved total arterial compliance [7] and arterial compliance improved 55 
by 28% to the level observed in endurance-trained individuals after infusion of antioxidants in 56 
sedentary individuals [8]. 57 
Fibroblast growth factor 21 (FGF21) is a novel hormone that is predictive of cardio-metabolic 58 
disorders [9]. FGF21 protects against cardiac hypertrophy, cardiac dilation and cardiac dysfunction 59 
in animal models [10]. However, people with cardiovascular diseases have increased resting 60 
concentrations of circulating FGF21 [11], suggesting either a compensatory cardioprotective effect of 61 
FGF21 or FGF21 resistance in cardiovascular disease states. FGF21 concentration is positively 62 
associated with carotid intima-media thickness and PWV in patients on haemodialysis [12] and 63 
patients with type 2 diabetes [13]. These results imply a potential link between FGF21 and arterial 64 
stiffness, possibly through the moderation of oxidative stress. We speculated that FGF21 could 65 
improve changes in arterial stiffness associated with ageing and exercise by reducing oxidative stress. 66 
For example, both in vivo and in vitro administration of FGF21 in animals increased the expression of 67 
genes involved in antioxidative pathways, including mitochondrial uncoupling proteins (Ucp2 and 68 
Ucp3), superoxide dismutase-2, and decreased oxidative stress mediated by reactive oxygen species 69 
production [14,15]. Protein and mRNA expression of FGF21 also increased in cultured cardiac 70 
endothelial cells and hepatocytes treated with oxLDL [16,17].  71 
Chronic FGF21 administration in both humans and mice increased plasma adiponectin 72 
concentration in a dose-dependent manner [18,19]. Further following myocardial infarction, 73 
adiponectin-null mice receiving FGF21 treatment had a blunted FGF21 response, which resulted in 74 
decreased capillary density, increased myocyte apoptosis and increased proinflammatory cytokine 75 
expression [20]. FGF21-deficient mice administered with adiponectin also exhibited alleviated 76 
atherosclerotic plaque formation [21]. These results suggest that adiponectin may be a downstream 77 
effector of the FGF21 pathway and that the FGF21–adiponectin axis may mediate the cardioprotective 78 
effects through the upregulation of genes involved in antioxidant pathways to improve arterial 79 
stiffness. Unlike FGF21, the links between adiponectin and arterial stiffness have been studied [22]. 80 
Adiponectin concentrations in hypertensive patients are negatively associated with PWV and plasma 81 
adiponectin concentrations independently predict arterial stiffness progression [23]. Adiponectin 82 
could influence arterial stiffness through the associated increase in antioxidant activity, which 83 
increases vasodilation and reduces systemic oxidative stress [24]. FGF21 and adiponectin 84 
concentrations increases with ageing, even in healthy individuals [25,26]. However, whether the 85 
FGF21–adiponectin-related increase in expression of genes involved in antioxidative pathways is 86 
associated with the regulation of arterial stiffness, and its interaction with habitual exercise and 87 
ageing, is not known. Therefore, the aim of this study was to explore the associations between the 88 
FGF21–adiponectin axis with oxidative stress and arterial stiffness, under the influence of ageing and 89 
habitual exercise. We hypothesised that age-related increase in FGF21 is associated with an increase 90 
in oxidative stress and arterial stiffness. We also hypothesised that habitual exercise-related decrease 91 
in FGF21 is associated with a decrease in oxidative stress and arterial stiffness. 92 
2. Materials and Methods  93 
Participants 94 
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Eighty participants from the Exercise for Life across Asia (ELIXA) cohort were recruited and 95 
assigned to four equal groups (n = 20 each) based on age and exercise history: Younger (18–36 years 96 
old) Active (YA) and Sedentary (YS), and Older (45–80 years old) Active (OA) and Sedentary (OS). 97 
The active and sedentary subgroups, within each age group, were matched for sex and age, in 5-year 98 
intervals. Exercise profiles of the participants were based on self-declared five-year history of exercise 99 
participation (type, duration, frequency and intensity). The YA and OA groups participated in ≥3 100 
sessions/week of moderate to vigorous intensity aerobic exercises for ≥45-min/session. These exercise 101 
participation criteria were within the recommended exercise guidelines of 75–150 min/week for 102 
moderate-to-vigorous intensity exercise [27]. The YS and OS groups engaged in <2 sessions/week of 103 
light intensity aerobic exercises, lasting <30 min/session. Exercise intensity was classified using 104 
descriptors that were based on the talk test [28] and breathing or heart rate responses, according to 105 
the global physical activity questionnaire [29]. The participants selected their individual exercise 106 
intensity based on these descriptors and the research team was available to provide guidance if 107 
needed. Light intensity exercises were described as activities causing a slight increase in breathing or 108 
heart rate, with participants being able to talk comfortably while doing the activity. Moderate to 109 
vigorous intensity exercises were described as activities requiring moderate to hard physical effort, 110 
causing larger increases in breathing or heart rate, with participants being unable to talk comfortably 111 
while doing the activity. Exercise profile was calculated by multiplying the sessions per week by the 112 
time spent per session for each exercise, and the total sum was reported as weekly exercise duration. 113 
The participants were non-smokers and non-habitual alcohol drinkers and female participants were 114 
not on oral contraceptives or hormone replacement therapy. All the participants were assessed and 115 
documented to be “healthy” (free from disease, medication and treatment) through medical 116 
screening by an appointed clinical service provider (Raffles Medical Group, Singapore). None of the 117 
participants recruited were obese or in the high-risk category of body mass index (BMI) for Asians 118 
(i.e. BMI was ≤27.5 kg/m2 for all participants) [30]. The medical screening included family history of 119 
diseases, assessment of blood pressure, height, weight, vision, urinalysis, and physical examination. 120 
The participants were recruited through posters, social media, and community outreach events. The 121 
participants were briefed on the nature and risks involved in the study and their right to withdraw 122 
their participation. All subjects gave their written informed consent for inclusion before they 123 
participated in the study. The study was conducted in accordance with the Declaration of Helsinki, 124 
and the protocol was approved by the institutional review board of Nanyang Technological 125 
University (IRB-2015-05-029). 126 
Anthropometry and blood sample collection  127 
The participants abstained from alcohol, caffeine and dietary supplementation, kept to their 128 
regular diet and sleep routines for 24 h and refrained from physical exercise for 48 h before their visits 129 
to the laboratory. On the day of the trial, participants arrived between 0830 h and 0930 h after an 130 
overnight fast and declared that they were well to proceed with the trial procedures and had their 131 
blood pressure (BP) measured (UM-102, A&D Medical, Japan). Pulse pressure was calculated as the 132 
difference between systolic and diastolic BP. Nude body weight was measured using an electronic 133 
scale (Seca 803, SECA, Hamburg, Germany) and height was measured using a stadiometer (Seca 217, 134 
SECA). BMI was calculated as body mass (kg) divided by height (m) squared. Waist circumference 135 
(WC) was recorded using a Gulick tape (Seca 201, SECA) which was placed snugly at the waistline, 136 
midway between the lowest ribs and iliac crest in a standing position. WC was measured thrice, 137 
recorded to the nearest 0.1 cm in triplicate and averaged from the measurements. 138 
A baseline venous blood sample was collected from the forearm into serum and dipotassium 139 
ethylenediaminetetraacetic acid (K2 EDTA) vacutainer tubes (4 mL) and placed on ice (4 oC) 140 
immediately. Fasted serum (4 mL) were analysed for triglycerides (TG), total cholesterol (TC), high-141 
density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) (Siemens 142 
ADVIA 1800 and ADVIA Chemistry XPT) by a licensed pathology laboratory (Quest Laboratories, 143 
Singapore). Fasted glucose concentration was measured immediately after the blood sampling 144 
procedure using a handheld glucometer (Accu-Chek, Roche). Blood samples in the EDTA tubes were 145 
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centrifuged at 1400 × g at 4 oC for 15 min. Plasma supernatant was extracted and stored in aliquots 146 
(120 µL) in microcentrifuge tubes (Axygen, Corning Life Sciences) at  ̶ 80 oC for analysis of 147 
concentration of FGF21, oxLDL and adiponectin. 148 
Arterial stiffness parameters 149 
Arterial stiffness was measured indirectly using PWV between the carotid and femoral arteries 150 
(SphygmoCor XCEL, AtCor Medical Pvt, Ltd, NSW, Australia). Blood pressure cuffs were wrapped 151 
around the right upper thigh (femoral artery) with the participants wearing comfortable casual attire. 152 
The participants rested quietly in a supine position for 15 min before measurements of arterial pulse 153 
pressure waveforms started. PWV was measured simultaneously with pressure transducers, by 154 
acquiring a carotid pulse by applanation tonometry and a femoral pulse by volumetric displacement, 155 
within an inflated cuff around the upper thigh. The pulse waves were captured electronically on a 156 
computer using the SphygmoCor system and accepted by the system after consistent high-quality 157 
waveforms were measured. An average of approximately 3–5 measurements were taken.  158 
Bioassays 159 
Plasma FGF21 concentration was measured with undiluted samples using a commercially 160 
available enzyme-linked immunosorbent assay (ELISA) according to the instructions of the 161 
manufacturer (DF2100; R&D Systems, Inc., Minnesota). Plasma adiponectin concentration was 162 
measured with 500-fold dilution of the plasma samples, using the Adiponectin Human ProcartaPlex 163 
Simplex kit (eBioscience, Affymetrix, Vienna, Austria) according to the manufacturer’s instructions. 164 
The assay samples were read on the Bio-Plex 200 System (Bio-Rad Laboratories, Inc, CA, USA) and 165 
the concentrations for each well were analysed with the Bio-Plex Manager Software. Human plasma 166 
oxLDL concentrations were measured with 6561-fold dilution of plasma samples, using a 167 
commercially available ELISA kit according to the manufacturer’s instructions (Mercodia oxLDL 168 
ELISA, Sweden). Intra- and inter-assay variation for our assays were < 5% for FGF21 and adiponectin 169 
concentrations and < 6% for oxLDL concentration. 170 
Statistics 171 
All statistical analyses were performed using IBM Statistical Package for Social Sciences (SPSS), 172 
version 23 (IBM Corp., Armonk, NY, USA). A sample size of 80 participants (20 per group) was 173 
needed for the trial to have 80% power to detect a two-sided hypothesis test at an α level of 0.05 174 
(effect size of 0.64) (G*Power, version 3.1, Germany).  Numerical variables are presented as means 175 
and standard deviations (SD). The participant characteristics were analysed using two-way analysis 176 
of variance (ANOVA), with age, exercise and age × exercise as fixed effects, to assess potential 177 
differences between age and exercise groups at baseline. PWV and blood-related parameters were 178 
also analysed using two-way ANOVA (Age × Exercise). The normality and heterogeneity of variance 179 
were tested using the Shapiro-Wilk test and Levene’s test respectively. To adjust for potential 180 
confounding factors, sex was analysed as a categorical control variable, and BMI and WC were 181 
treated as continuous predictor variables in the two-way ANOVA analyses. Plasma FGF21, plasma 182 
adiponectin and PWV data did not meet the criteria for normal distribution. Logarithmic 183 
transformation was performed before analysis for PWV data and plasma FGF21 concentrations. The 184 
data for plasma adiponectin concentration was transformed using the cube-root function. Pearson’s 185 
correlation was used to evaluate associations between two variables. A partial correlation model was 186 
used to adjust for potential confounding variables such as sex or weekly exercise duration in the 187 
correlation analysis between two variables. Some of the sedentary participants did not engage in 188 
weekly exercise, resulting in clustering of data at the low end for weekly exercise duration. Weekly 189 
exercise duration was thus stratified into 4 groups based on 0 min (n = 26), <180 min (n = 19), 180–360 190 
min (n = 19) and >360 min (n = 16), to ensure sufficient participants within each group and an even 191 
distribution of participants across the groups. One-way ANOVA was used to analyse the 192 
relationships between weekly exercise duration groups with PWV and oxLDL concentration. To 193 
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adjust for confounding factors, age was treated as a continuous variable and sex was analysed as a 194 
categorical control variable in the one-way ANOVA model. All data in the tables and figures are 195 
presented using the original untransformed data. Statistical significance was accepted if p < 0.05. 196 
3. Results 197 
Table 1. Participant demographics, exercise history, anthropometry and blood pressure. 198 
 
Young 
Sedentary 
(YS) 
Young 
Active 
(YA) 
Older Sedentary 
(OS) 
Older 
Active 
(OA) 
Age Exercise 
Age × 
Exercise 
n 20 20 20 20    
Sex n (M/F) 10/10 10/10 11/9 12/8    
Exercise intensity Light 
Mod-
High 
Light 
Mod-
High 
   
Exercise 
(min/week) 
18 (27) 369 (177) 16 (28) 350 (214) 0.747 <0.001 0.790 
Age (years) 28 (5) 28 (5) 56 (7) 57 (9) <0.001 0.668 0.668 
Body mass (kg) 59.3 (7.2) 
60.4 
(13.8) 
64.3 (13.5) 
62.9 
(11.8) 
0.150 0.937 0.619 
Height (cm) 169.6 (8.2) 
166.8 
(10.1) 
163.9 (8.7) 
167.5 
(8.6) 
0.208 0.852 0.116 
BMI (kg/m2) 20.6 (2.2) 21.5 (2.2) 23.8 (4.0) 22.2 (2.4) 0.003 0.563 0.053 
WC (cm) 72.9 (5.3) 72.8 (7.0) 82.1 (9.2) 77.8 (8.5) <0.001 0.207 0.216 
Systolic BP 
(mmHg) 
109 (8) 110 (5) 121 (11) 119 (12) <0.001 0.891 0.577 
Diastolic BP 
(mmHg) 
67 (7) 64 (5) 76 (8) 70 (8) <0.001 0.006 0.247 
PP (mmHg) 38 (9) 39 (9) 38 (8) 42 (12) 0.500 0.229 0.469 
TC (mmol/l) 5.0 (0.6) 4.8 (1.1) 5.6 (0.7) 5.9 (0.9) <0.001 0.760 0.202 
HDL-C (mmol/l) 1.6 (0.3) 1.9 (0.5) 1.6 (0.5) 1.9 (0.4) 0.988 0.012 0.707 
LDL-C (mmol/l) 3.0 (0.6) 2.6 (0.7) 3.4 (0.6) 3.5 (0.8) <0.001 0.452 0.082 
TG (mmol/l) 0.8 (0.2) 0.7 (0.2) 1.2 (0.4) 1.0 (0.4) <0.001 0.003 0.944 
Antioxidants 2020, 9, x FOR PEER REVIEW 6 of 17 
Fasted glucose 
(mmol/l) 
4.8 (0.3) 4.9 (0.4) 5.0 (0.3) 5.0 (0.4) 0.043 0.583 0.814 
Body mass index (BMI), waist circumference (WC), blood pressure (BP), pulse pressure (PP), total 199 
cholesterol (TC), High density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol 200 
(LDL-C), Triglyceride (TG), Mod = moderate. Values are mean (SD). P values are indicated in the last 201 
three columns and statistically significant values are indicated with a bold type interface. 202 
Participant demographics, anthropometry, blood pressure, lipids and glucose 203 
The demographic, physical and blood pressure profiles of the eighty participants are presented 204 
in Table 1. Age was equally distributed between active and sedentary participants in both younger 205 
and older groups. Sex was equally matched between the YA and YS group and there was one more 206 
male participant in the OA than in the OS group. There were no significant differences in body mass 207 
and height among different age and exercise groups. However, BMI was significantly lower in the 208 
younger than the older group (p = 0.003), independent of exercise status. Compared with younger 209 
participants, older participants also had higher WC (p < 0.001), independent of exercise habits (Table 210 
1). Compared with the younger participants, older participants had higher systolic (10%) and 211 
diastolic (12%) BP (all p < 0.001), regardless of exercise habits. Diastolic BP was 6% lower in active 212 
than sedentary groups (p < 0.006) (Table 1). TC, LDL-C and TG concentrations were higher in older 213 
than younger adults (all p < 0.001), while HDL-C was higher (p = 0.012), and TG was lower in active 214 
than in sedentary individuals (p = 0.003) (Table 1). Fasted blood glucose concentrations were higher 215 
in older than younger adults (p = 0.043) (Table 1). 216 
Associations between habitual exercise and ageing with PWV and oxLDL 217 
Age was positively correlated with PWV (r = 0.624, p < 0.001, Fig 1A) and with plasma oxLDL 218 
concentration (r = 0.470, p < 0.001, Fig 1B), even after adjusting for weekly exercise duration (r = 0.637, 219 
p < 0.001) and sex (r = 0.461, p < 0.001) in a partial correlation analysis. PWV (p = 0.340) and oxLDL 220 
concentrations (p = 0.536) did not differ across the weekly exercise duration groups (Fig 1C and 1D), 221 
even after adjusting for sex (p = 0.185) and age (p = 0.373).  222 
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Figure 1. Pearson’s correlation between age with pulse wave velocity (PWV) (A), as a surrogate 224 
marker for arterial stiffness, and oxidised low-density lipoprotein (oxLDL) concentrations (B). One-225 
way analysis of variance was conducted for PWV (C) and oxLDL concentrations (D) between weekly 226 
exercise duration, stratified across 4 groups. ns = not significant. 227 
Associations of exercise and ageing with FGF21, adiponectin, oxidative stress and PWV 228 
Plasma samples from two participants were insufficient for determination of FGF21 229 
concentration and were excluded from the analysis. The FGF21 concentrations reported are from 78 230 
participants: YS (n = 19), YA (n = 19), OS (n = 20), OA (n = 20). Circulating FGF21 concentration was 231 
not different between older and younger groups, regardless of exercise habits (p = 0.097), even after 232 
adjusting for sex, BMI and WC (p = 0.397) (Fig 2A). However, fasted circulating concentration of 233 
FGF21 was 9% lower in active participants than their sedentary counterparts regardless of age (p = 234 
0.011), even after adjusting for sex (p = 0.012) (Fig 2A). The interaction effect of age and exercise was 235 
not significant for plasma FGF21 concentration (p = 0.475) (Fig 2A). 236 
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Figure 2. Two-way analysis of variance (age × exercise) of fibroblast growth factor 21 (FGF21) (A), 238 
adiponectin (B), oxidized low-density lipoprotein (oxLDL) (C) concentrations and pulse wave 239 
velocity (PWV) (D) in younger active (YA) (n = 20, M/F = 10/10) and sedentary (YS) (n = 20, M/F = 240 
10/10), and in older active (OA) (n = 20, M/F = 11/9) and sedentary (OS) (n = 20, M/F = 12/8) individuals. 241 
Two-way ANOVA for FGF21 concentration was conducted only for YA (n = 19, M/F = 10/9), YS (n = 242 
19, M/F = 9/10), OA (n = 20, M/F = 11/9) and OS (n = 20, M/F = 12/8) groups *** = p < 0.001 for age. † = p 243 
< 0.05 for exercise status. 244 
Circulating adiponectin concentration was not significantly different between active and 245 
sedentary groups (p = 0.821, Fig 2B) or between younger and older groups (p = 0.642, Fig 2B), even 246 
after adjusting for sex, BMI and WC (p = 0.399). No significant interaction effect was observed for 247 
plasma adiponectin concentration (p = 0.418) (Fig 2B).  248 
Compared with their younger counterparts, older adults had 25.6% higher basal plasma oxLDL 249 
concentrations (p < 0.001), even after adjusting for sex, BMI and WC (p = 0.001) (Fig 2C). Habitual 250 
exercise was not associated with oxLDL concentrations (p = 0.275), even after adjusting for sex (p = 251 
0.259). There was no significant interaction effect of age and exercise for oxLDL concentration (p = 252 
0.583) (Fig 2C).  253 
Compared with the younger participants, the PWV in older participants was 0.2-fold higher (p 254 
< 0.001, Fig 2D). Adjusting for sex, BMI and WC did not influence these differences observed in PWV 255 
with age. However, PWV was not statistically different between active and sedentary groups (p = 256 
0.09), even after adjusting for sex (p = 0.065, Fig 2D). No significant interaction between age and 257 
exercise was observed for PWV. 258 
Correlations between FGF21, adiponectin, oxLDL and PWV 259 
When analysed as an entire cohort, the correlation between plasma FGF21 concentration and 260 
PWV was not statistically significant (r = 0.220, p = 0.054, n = 78, Table 2) and this relationship did not 261 
change in subgroup analyses conducted by age and exercise habits. Adjusting for sex in a partial 262 
correlation analysis between FGF21 concentration and PWV was statistically significant (r = 0.232, p 263 
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= 0.044). In contrast, higher plasma adiponectin concentration was negatively correlated with PWV 264 
(r = –0.384, p < 0.001, n = 80, Table 2). Plasma oxLDL concentration was positively correlated with 265 
PWV (r = 0.367, p = 0.001, n = 80, Table 2). When analysed as an entire group, there were no significant 266 
correlations between plasma FGF21, adiponectin or oxLDL concentrations (all p > 0.05, n = 80, data 267 
not shown) and adjusting for sex in a partial correlation model did not affect the results presented.   268 
For subgroup analysis, plasma adiponectin concentration was negatively correlated with PWV 269 
within the younger group (r = –0.359, p = 0.025, n = 40, Table 2). However, there was a stronger 270 
correlation between adiponectin and PWV in the older group (r = –0.509, p = 0.001, n = 40, Table 2), 271 
when examining all activity groups together. In subgroup analysis, plasma oxLDL concentration was 272 
also positively correlated with plasma FGF21 concentration in the older (r = 0.345, p = 0.029, n = 40), 273 
but not in the younger (r = –0.132, p = 0.431, n = 38) group, even after adjusting for sex in a partial 274 
correlation model, independent of activity status.   275 
In subgroup analysis, plasma adiponectin concentration was negatively correlated with PWV in 276 
the sedentary participants (r = –0.511, p = 0.001, n = 40), but not in active participants (r = –0.198, p = 277 
0.220, n = 40), when examining all ages together (Table 2). In contrast, in active individuals, a positive 278 
correlation between plasma oxLDL concentration and PWV was found (r = 0.452, p = 0.003, n = 40) 279 
(Table 2). Adjusting for sex in a partial correlation analysis did not affect these subgroup correlations 280 
in the sedentary and active groups.  281 
Table 2. Pearson’s correlations (r) between FGF21, adiponectin, oxLDL and pulse wave velocity 282 
(PWV). 283 
 n M/F Biomarker PWV 
Total 78 42/36 FGF21 
0.220 
(0.054) 
 80 43/37 Adiponectin 
–0.384 
(<0.001) 
 80 43/37 oxLDL 
0.367 
(0.001) 
Younger 38 19/19 FGF21 
–0.081 
(0.634) 
 40 20/20 Adiponectin 
–0.359 
(0.025) 
 40 20/20 oxLDL 
0.157 
(0.339) 
Older 40 23/17 FGF21 
0.262 
(0.103) 
 40 23/17 Adiponectin 
–0.509 
(0.001) 
 40 23/17 oxLDL 
0.174 
(0.283) 
Active 39 21/18 FGF21 
0.083 
(0.614) 
 40 21/19 Adiponectin 
–0.198 
(0.220) 
 40 21/19 oxLDL 
0.452 
(0.003) 
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Sedentary 39 21/18 FGF21 
0.272 
(0.099) 
 40 22/18 Adiponectin 
–0.511 
(0.001) 
 40 22/18 oxLDL 
0.259 
(0.111) 
Values are unadjusted Pearson’s r on top and p values in brackets below. Values in bold type interface 284 
represent statistically significant correlations. 285 
4. Discussion 286 
The present study investigated the associations between ageing and exercise habits with 287 
oxidative stress and a surrogate measurement of arterial stiffness, PWV, in healthy individuals. To 288 
our knowledge, this study is the first to explore the relationship between the FGF21- and adiponectin-289 
associated pathway with oxidative stress and PWV. Compared with younger individuals, older 290 
individuals had higher circulating plasma oxLDL concentrations and higher PWV. These results are 291 
consistent with previous findings that ageing independently increases oxidative stress by 1.2–3-fold 292 
and PWV by ~2-fold [2,31,32]. In our study, oxLDL concentration was positively correlated to PWV. 293 
These results extend the current understanding that an age-related increase in oxidative stress is 294 
associated with arterial stiffening even in healthy individuals. Consistent with our results, oxidative 295 
stress was independently and positively associated with PWV in middle-aged and older adults, 296 
regardless of health status in previous studies [33,34]. Oxidative stress contributes to arterial stiffness 297 
by decreasing endothelial nitric oxide synthesis and bioavailability, which impairs arterial 298 
compliance and increases arterial stiffness [35,36]. Compared to younger adults, healthy elderly 299 
individuals had increased oxLDL concentration, which was negatively related to forearm blood flow 300 
when subjected to reactive hyperaemia, suggesting that age-associated increase in oxidative stress 301 
influenced vascular function and arterial stiffness [32].  302 
Plasma FGF21 concentrations were not different between the age groups in our study, implying 303 
that the age-associated increase in oxidative stress was unlikely mediated by FGF21. In contrast, 304 
earlier findings suggested that FGF21 concentration increased with age in healthy individuals (aged 305 
5–80 years) [25], and was involved in the regulation of oxidative stress [15-17]. Moreover, increased 306 
intracellular stress signalling due to oxLDL administration resulted in increased FGF21 expression in 307 
animal cardiac cells and hepatocytes [16,17]. Administration of FGF21 also protected against 308 
oxidative stress in human endothelial cells, supporting the antioxidative role of FGF21 in improving 309 
PWV [15]. The positive associations of FGF21 with arterial stiffness in male and female patients on 310 
haemodialysis [12] and patients with type 2 diabetes [13], and in obese women [37] could also suggest 311 
compensatory antioxidative effects of FGF21 on increasing arterial stiffness. Collectively, these earlier 312 
results support the role of FGF21 in mediating an age-associated increase in arterial stiffness by 313 
decreasing oxidative stress. The different findings in our study could be due to the participant 314 
inclusion criteria, which was limited to a clinically healthy (free from metabolic and cardiovascular 315 
diseases) and non-obese population. The antioxidant and cardio-protective effects of FGF21 could be 316 
more obvious in diseased populations, who have higher oxidative stress and higher fasted circulating 317 
FGF21 concentrations [11,38]. In addition, most of the mechanistic studies involving FGF21 and 318 
oxidative stress were done on animal or in vitro models, which are difficult to translate to the healthy 319 
participants in our study. Contrary to the associated increase in antioxidant activity with FGF21 in 320 
attenuating arterial stiffness [15-17], the present study showed no age-associated differences in FGF21 321 
concentration in healthy young and older adults. Our results appear to suggest that FGF21 is unlikely 322 
involved in age-associated increases in oxidative stress and arterial stiffness. Our findings differed 323 
from earlier studies reporting an age-associated increase in FGF21 concentration [25,39]. This 324 
difference in results could be due to differences in method of data analysis and profile of subjects. 325 
For example, one study included participants from 5–80 years old, and analysed age as a categorical 326 
variable in 5 groups [25] while participants in another study were 90–100 years old, with 327 
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heterogenous health status, such as surgery for hip dysplasia [39]. The profile of these subjects 328 
differed from our study, who were all healthy and with age ranging from 18–36 in the younger group, 329 
and from 45–80 in the older group. We compared FGF21 concentrations between younger and older 330 
groups, rather than a multiple linear regression [25] or correlation analyses [39]. Our sample size is 331 
also relatively small compared with earlier studies that achieved a positive association between 332 
FGF21 concentration and age [25,39]. The borderline significant positive correlation between FGF21 333 
concentration and PWV suggests that increased circulating FGF21 concentration or basal FGF21 334 
resistance may be related to higher arterial stiffness, perhaps through anti-inflammatory mechanisms 335 
rather than antioxidative pathways. Instead of the direct FGF21-associated effects on antioxidant 336 
pathways with arterial stiffness, FGF21 may also indirectly affect arterial stiffness through oxLDL-337 
induced pyroptosis and related cellular dysfunction through specific receptors [40]. 338 
In this study, the concentration of the FGF21-downstream-effector, adiponectin [19,41], was 339 
negatively correlated with PWV, suggesting that adiponectin may be linked to lower arterial stiffness 340 
even in healthy individuals, independent of FGF21. Adiponectin could improve arterial stiffness 341 
through an increase in proteins involved in antioxidant pathways [24]. In mice, adiponectin 342 
decreased systemic oxidative stress and normalised endothelial cell function through increased nitric 343 
oxide production, which could in turn decrease arterial stiffness [42,43]. In humans, an inverse 344 
relationship was also reported between plasma adiponectin concentration and PWV, supporting the 345 
potential role of adiponectin in improving arterial stiffness [44]. In the sub-group correlation 346 
analyses, the negative correlation between plasma adiponectin concentration and PWV was more 347 
apparent in the older than the younger participants, and in the sedentary than the active participants. 348 
Plasma FGF21 concentration was also positively correlated with oxLDL concentration only in the 349 
older but not the younger group. Our preliminary findings imply that FGF21 and adiponectin may 350 
independently act as compensatory responses to mitigate oxidative stress and arterial stiffness, 351 
respectively, especially in older and sedentary adults. These findings also suggest that different 352 
mechanisms may drive arterial stiffness in young and older adults. For example, in adults <50 years 353 
old, age-associated arterial stiffness was due to an increase in the magnitude of wave reflection in 354 
peripheral arteries, whereas in individuals >50 years old, age-associated arterial stiffness was due to 355 
increased wave velocity resulting from a less compliant central aorta [2,31]. Taken together, our 356 
results suggest that adiponectin may regulate age-associated arterial stiffening, independent of 357 
FGF21, especially in healthy older adults. 358 
The plasma concentration of oxLDL and PWV in the present study were not different between 359 
habitually active and sedentary groups, suggesting that habitual exercise may not affect oxidative 360 
stress and arterial stiffness. However, others have reported a negative association between habitual 361 
exercise participation and arterial stiffness in healthy young adults [45,46]. Short-, medium- and long-362 
term exercise have been found to reduce arterial stiffness in younger populations. For example, six 363 
days of endurance training at 65% of peak oxygen consumption in young healthy males (~25 years 364 
old) reported an 8% improvement in PWV [46] and eight weeks of aerobic exercise at 60–80% heart 365 
rate reserve also improved PWV in both healthy males and females (~41 years old) [47]. A 24-year 366 
longitudinal study in healthy males and females (starting from age 13 years old) demonstrated that 367 
long term vigorous habitual physical activity was associated with improved arterial stiffness [45].  A 368 
6-week exercise and dietary intervention in children who were obese also reduced oxLDL 369 
concentration [48]. These results were also found in adult men and women, aged 18–65 years, where 370 
4 weeks of moderate intensity exercise decreased oxLDL concentration by 14% [49]. These earlier 371 
findings suggest that habitual exercise improves arterial stiffness regardless of age and that exercise-372 
induced improvement in arterial stiffness could be mediated by a reduction in oxidative stress. The 373 
discrepancies in earlier findings which reported improvements in arterial stiffness with exercise were 374 
done mostly on only younger [45,46] or middle-aged [47] adults, which differed from 45–80 (older 375 
group) age group in our study. The effects of exercise on attenuating arterial stiffness may be age 376 
dependent, as longer physical activity duration decreased PWV by 7% only in older adults aged >60 377 
years [50]. The favourable effects of exercise on arterial stiffness may be more apparent for higher 378 
intensity exercises [46,47], unlike our study which included moderate to high intensity exercises. The 379 
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history of exercise duration and intensity for active participants was documented using a self-380 
reported approach, which differed from other studies with controlled exercise interventions, 381 
objectively quantified exercise intensities [46,47] and accelerometery-measured physical activity [50]. 382 
Our cross-sectional study design could have contributed to the disparity in results with earlier 383 
longitudinal studies [45] or intervention studies, which administered chronic exercise bouts [48,49]. 384 
Our study compared PWV between habitually active and sedentary individuals, while earlier 385 
exercise intervention studies recruited participants of various activity profiles including < 2 h/week of 386 
low to moderate intensity exercise [46] or VO2max ~24 ml/min/kg [47]. These differences in study 387 
design, study population and exercise intensity could have contributed to the disparity between our 388 
results and results that were reported previously on habitual exercise with oxidative stress and 389 
arterial stiffness.  390 
A key limitation of the present study is the cross-sectional design, which could demonstrate 391 
associations but not prove causality between higher oxLDL and FGF21 concentrations or lower 392 
adiponectin concentrations, and the state of arterial stiffness. Given that plasma oxLDL concentration 393 
was measured as a surrogate marker of oxidative stress, the exact mechanisms driving an association 394 
between oxidative stress and PWV cannot be determined from this study. Future studies should 395 
investigate the effects of FGF21 on nitric oxide and endothelial function as potential pathways in 396 
mediating arterial stiffness. We did not account for cysteine or pro-inflammatory cytokines and 397 
chemokines of the participants in this present study, which could have affected the FGF21 and 398 
oxidative stress concentrations measured. These present findings are based on our inclusion criteria 399 
of healthy, non-smokers, non-habitual alcohol drinkers and females who were not on oral 400 
contraceptives or hormone replacement therapy. These inclusion criteria were designed to isolate the 401 
effects of habitual exercise and ageing on the parameters studied, but the results may not be 402 
generalized or representative of other biomarkers and populations. Future studies could possibly 403 
recruit individuals who are more representative of the general population. This study provided 404 
useful early data on the potential links between oxidative stress, FGF21 and adiponectin with age-405 
related arterial stiffness. However, as the current sample size is relatively small, future studies 406 
involving a larger elderly cohort are needed to shed more light on the mechanistic pathways 407 
regulating the interactions on oxidative stress, FGF21, adiponectin and arterial stiffness with age. 408 
Future studies could also administer exercise interventions and quantify exercise intensity using 409 
more objective methods in order to better investigate the effects of exercise on FGF21, oxidative stress 410 
and arterial stiffness. Understanding the underlying mechanisms of oxidative stress-associated 411 
arterial stiffness can potentially contribute to the development of therapeutic targets to improve 412 
arterial compliance and reduce cardiovascular risk.  413 
In summary, this study demonstrated that ageing is associated with an increase in oxidative 414 
stress and arterial stiffness, but this is unlikely mediated through FGF21 and adiponectin. Habitual 415 
exercise unlikely attenuates oxidative stress or arterial stiffness in healthy individuals. 416 
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